Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Core Insights - Cogent Biosciences, Inc. announced four preclinical poster presentations at the 2025 AACR Annual Meeting, showcasing its focus on precision therapies for genetically defined diseases [1][2] Group 1: Poster Presentations - The first poster details a potent KRAS (ON) inhibitor selective for mutant KRAS over HRAS and NRAS, scheduled for presentation on April 30, 2025 [2] - The second poster presents CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor, to be showcased on April 28, 2025 [2] - The third poster features CGT4859, a reversible and selective FGFR2/3 inhibitor with superior target coverage of resistance mutations, presented on April 29, 2025 [2] - The fourth poster introduces CGT4255, an EGFR sparing, pan-mutant HER2 candidate with potential best-in-class brain penetration, also scheduled for April 29, 2025 [2] Group 2: Inducement Grant - The Compensation Committee of Cogent's Board approved an inducement equity award for a new employee, consisting of a nonqualified option to purchase 9,700 shares of common stock, with a 10-year term and a 4-year vesting schedule [3] Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its leading clinical program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors [4][5] - The company is also advancing a Phase 1 study of its novel FGFR2 inhibitor and developing a portfolio of targeted therapies for mutations in ErbB2, PI3Kα, and KRAS [5]